IPH — Innate Pharma SA Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapMomentum Trap

Annual income statement for Innate Pharma SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	R2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	56.2	12.1	49.6	51.9	12.6
Cost of Revenue
Gross Profit	52.6	9.05	46	49	—
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	55.1	59.9	107	64.6	64.2
Operating Profit	1.08	-47.8	-57.4	-12.7	-51.6
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-0.829	-45.5	-58	-7.57	-49.5
Provision for Income Taxes
Net Income After Taxes	-0.829	-45.5	-58	-7.57	-49.5
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-64	-52.8	-58.1	-7.57	-49.5
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-64	-52.8	-58.1	-7.57	-49.5
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.011	-0.572	-0.213	-0.094	-0.61
Dividends per Share